Once a challenging disease to recognize with few treatment options, macular telangiectasia type 2 (MacTel) is entering a new era. In this informative and compelling Milestone Moments interview, Timothy G. Murray, MD, MBA, FASRS, and Charles C. Wykoff, MD, PhD, FASRS, discuss how advances in retinal imaging have improved diagnosis and explore the development of a new cell-based therapy designed to slow disease progression.

Hear the story behind the technology, what clinical trials have shown, and how retina specialists are approaching patient selection, surgical implantation, and counseling as this new treatment enters clinical practice.

(Published 10.2026)